SCYNEXIS, Inc. (SCYX)

Market Cap	53.61M
Revenue (ttm)	140.14M
Net Income (ttm)	67.04M
Shares Out	37.75M
EPS (ttm)	1.39
PE Ratio	1.02
Forward PE	2.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,368
Open	1.400
Previous Close	1.410
Day's Range	1.370 - 1.460
52-Week Range	1.350 - 3.870
Beta	1.57
Analysts	Buy
Price Target	n/a
Earnings Date	May 9, 2024

About SCYX

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The co...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SCYX